$3.35
00.00%
Pre-Market: 4:02 PM EDT
15 minutes delayed
Design Therapeutics
DSGNNASDAQ
Design Therapeutics (NASDAQ:DSGN) Stock, Analyst Ratings, Price Targets, Predictions
Design Therapeutics Inc has a consensus price target of $5.4, established from looking at the 19 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, RBC Capital, and Wedbush on May 7, 2024, March 20, 2024, and March 20, 2024. With an average price target of $7 between Piper Sandler, RBC Capital, and Wedbush, there's an implied 108.96% upside for Design Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
RBC Capital
Wedbush
SVB Leerink
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Design Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/07/2024 | Buy Now | 258.21% | Piper Sandler | Yasmeen Rahimi | $6 → $12 | Upgrade | Neutral → Overweight | Get Alert |
| 03/20/2024 | Buy Now | 19.4% | RBC Capital | Leonid Timashev | → $4 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 03/20/2024 | Buy Now | 49.25% | Wedbush | Laura Chico | → $5 | Reiterates | Neutral → Neutral | Get Alert |
| 11/14/2023 | Buy Now | 19.4% | RBC Capital | Leonid Timashev | $7 → $4 | Maintains | Sector Perform | Get Alert |
| 08/15/2023 | Buy Now | 79.1% | Wedbush | Laura Chico | → $6 | Downgrade | Outperform → Neutral | Get Alert |
| 08/15/2023 | Buy Now | 79.1% | SVB Leerink | Joseph Schwartz | → $6 | Downgrade | Outperform → Market Perform | Get Alert |
| 08/15/2023 | Buy Now | 108.96% | RBC Capital | Leonid Timashev | $23 → $7 | Downgrade | Outperform → Sector Perform | Get Alert |
| 05/10/2023 | Buy Now | 586.57% | RBC Capital | Leonid Timashev | $24 → $23 | Maintains | Outperform | Get Alert |
| 05/10/2023 | Buy Now | 467.16% | Wedbush | Laura Chico | $20 → $19 | Maintains | Outperform | Get Alert |
| 05/04/2023 | Buy Now | — | Goldman Sachs | Madhu Kumar | — | Upgrade | Sell → Neutral | Get Alert |
| 03/15/2023 | Buy Now | 616.42% | RBC Capital | Leonid Timashev | → $24 | Reiterates | → Outperform | Get Alert |
| 12/09/2022 | Buy Now | 556.72% | SVB Leerink | Joseph Schwartz | $30 → $22 | Maintains | Outperform | Get Alert |
| 12/08/2022 | Buy Now | 616.42% | RBC Capital | Leonid Timashev | $29 → $24 | Maintains | Outperform | Get Alert |
| 08/09/2022 | Buy Now | 676.12% | Wedbush | Laura Chico | $21 → $26 | Maintains | Outperform | Get Alert |
| 06/10/2022 | Buy Now | 526.87% | Wedbush | Laura Chico | → $21 | Initiates | → Outperform | Get Alert |
| 05/24/2022 | Buy Now | 79.1% | Goldman Sachs | Madhu Kumar | $8 → $6 | Maintains | Sell | Get Alert |
| 05/10/2022 | Buy Now | 795.52% | SVB Leerink | Joseph Schwartz | $36 → $30 | Maintains | Outperform | Get Alert |
| 05/02/2022 | Buy Now | 795.52% | RBC Capital | Leonid Timashev | → $30 | Initiates | → Outperform | Get Alert |
| 01/19/2022 | Buy Now | 198.51% | Goldman Sachs | Madhu Kumar | → $10 | Initiates | → Sell | Get Alert |
FAQ
What is the target price for Design Therapeutics (DSGN) stock?
The latest price target for Design Therapeutics (NASDAQ:DSGN) was reported by Piper Sandler on May 7, 2024. The analyst firm set a price target for $12.00 expecting DSGN to rise to within 12 months (a possible 258.21% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Design Therapeutics (DSGN)?
The latest analyst rating for Design Therapeutics (NASDAQ:DSGN) was provided by Piper Sandler, and Design Therapeutics upgraded their overweight rating.
When was the last upgrade for Design Therapeutics (DSGN)?
The last upgrade for Design Therapeutics Inc happened on May 7, 2024 when Piper Sandler raised their price target to $12. Piper Sandler previously had a neutral for Design Therapeutics Inc.
When was the last downgrade for Design Therapeutics (DSGN)?
The last downgrade for Design Therapeutics Inc happened on August 15, 2023 when Wedbush changed their price target from N/A to $6 for Design Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Design Therapeutics (DSGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Design Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Design Therapeutics was filed on May 7, 2024 so you should expect the next rating to be made available sometime around May 7, 2025.
Is the Analyst Rating Design Therapeutics (DSGN) correct?
While ratings are subjective and will change, the latest Design Therapeutics (DSGN) rating was a upgraded with a price target of $6.00 to $12.00. The current price Design Therapeutics (DSGN) is trading at is $3.35, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.